Organization
University of Kansas Medical Center (KUMC)
3 abstracts
Abstract
Targeting minimal residual disease (MRD) in resected RAS mutated pancreatic cancer with vaccine TG01/QS-21 +/- PD-1 inhibitor, balstilimab: A randomized phase II study (TESLA).Org: University of Kansas Cancer Center, Kansas City, KS, University of Kansas Medical Center (KUMC), University of Kansas Medical Center, Department of Biostatistics & Data Science,
Abstract
Clinical validation of an activity-based enzyme assay for early stage lung cancer.Org: Hawkeye Bio, Inc., University of Kansas Medical Center (KUMC), Marmara University Pendik Research and Training Hospital, Vejle Hospital, University Hospital of Southern Denmark,
Abstract
Dares: A phase II trial of durvalumab and ablative radiation in extensive stage small cell lung cancer.Org: University of Chicago Medical Center, Chicago, IL, University of Kansas Medical Center, Department of Biostatistics & Data Science, University of Kansas Medical Center (KUMC), Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, University of Chicago,